Skip to main content

MOORE CAPITAL MANAGEMENT, LP

Position in RARE — Ultragenyx Pharmaceutical Inc.

CIK 1448574 NEW YORK, NY

Position in RARE

as of Mar 31, 2026 · filed May 15, 2026
Position Value
$3,291,915
-$1,308,085 QoQ
Shares Held
157,132
-21.4% QoQ
Ownership
0.160%
of shares outstanding
% of Portfolio
0.14%
of 13F equity value
Holder Rank
not a current holder
Holding Since
Mar 2023
13 quarters on record
Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Common Shares in RARE Over Time

Shares Held

Position Value (USD)

Derivatives in RARE

reported options exposure · as of Dec 31, 2025
CallValue
$9,275,900
CallShares
403,300
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Mar 31, 2026

MOORE CAPITAL MANAGEMENT, LP holds $51,235,346 across 22 Biotechnology names. RARE ranks #6 (6.4% of the industry book) .

# Ticker Company Shares Value (USD) Open
6 RARE
Ultragenyx Pharmaceutical Inc.
This page
157,132 $3,291,915

All Filings in RARE

Export CSV
19 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $3,291,915 157,132
2025-12-31 $9,275,900 403,300
2025-12-31 $4,600,000 200,000
2025-09-30 $8,121,600 270,000
2025-06-30 $7,272,000 200,000
2025-06-30 $10,544,400 290,000
2025-03-31 $8,690,400 240,000
2024-12-31 $2,103,500 50,000
2024-12-31 $10,307,150 245,000
2024-09-30 $13,609,750 245,000
2024-09-30 $5,555,000 100,000
2024-06-30 $10,069,500 245,000
2024-06-30 $4,110,000 100,000
2024-03-31 $8,637,650 185,000
2024-03-31 $3,501,750 75,000
2023-12-31 $8,846,700 185,000
2023-09-30 $5,347,500 150,000
2023-06-30 $4,843,650 105,000
2023-03-31 $1,203,000 30,000